March 20, 2024 07:41 AM EDTUpdated March 21, 04:53 PM

As focus shifts to oncology, BioNTech nabs Novartis exec as chief commercial officer

Ayisha Sharma

News Reporter

BioNTech has hired one of Novartis’ radioligand therapy leaders as its new chief commercial officer, as the company looks to pivot from reliance on its …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

As focus shifts to oncology, BioNTech nabs Novartis exec as chief commercial officer

Ayisha Sharma

News Reporter

Sign up to read this article for free.

Jazz wins approval for bispecific in biliary tract cancer

RFK Jr. and Elon Musk want to ban pharma ads. They wouldn't be the first to try

FDA adcomm raises risk questions on AstraZeneca’s Andexxa

Novartis seeks more bolt-on deals as it purchases neuro startup for up to $1.1B

At Jefferies, all that manufacturers want to talk about is GLP-1s

Are programs with compounded GLP-1s safe for your population?

As fo­cus shifts to on­col­o­gy, BioN­Tech nabs No­var­tis ex­ec as chief com­mer­cial of­fi­cer

Ayisha Sharma

News Reporter

Sign up to read this article for free.

Jazz wins ap­proval for bis­pe­cif­ic in bil­iary tract can­cer

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

FDA ad­comm rais­es risk ques­tions on As­traZeneca’s An­dexxa

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

At Jef­feries, all that man­u­fac­tur­ers want to talk about is GLP-1s

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

As focus shifts to oncology, BioNTech nabs Novartis exec as chief commercial officer

Jazz wins approval for bispecific in biliary tract cancer

RFK Jr. and Elon Musk want to ban pharma ads. They wouldn't be the first to try

FDA adcomm raises risk questions on AstraZeneca’s Andexxa

Novartis seeks more bolt-on deals as it purchases neuro startup for up to $1.1B

At Jefferies, all that manufacturers want to talk about is GLP-1s

Are programs with compounded GLP-1s safe for your population?